Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Vascular calcification and endothelial dysfunction (ED) contribute to the development of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Sevelamer, a non-calcium based phosphate binder, has been shown to attenuate cardiovascular calcification in CKD patients while the exact mechanism has not been clarified.

This study was designed to investigate the effect of short-term sevelamer treatment on both serum FGF23 levels concentrations and ED seen in CKD patients.

The researchers investigated the relationship between plasma FGF23 levels and the forearm blood flow response to ischemia in the forearm in a sizable series of incident stage 3-4 CKD patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gulhane School of Medicine
• Treatments: Calcium; Calcium acetate; Calcium, Dietary; Sevelamer

Criteria

Inclusion Criteria:

• CKD stage 4 patients

• Older than 18 years of age

• Non-diabetic

• Serum phosphorus > 5.5 mg/dl

Exclusion Criteria:

• Diabetes mellitus

• History of coronary artery disease

• Smokers

• Taking statins or renin-angiotensin blockers